Sintilimab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade from ProteoGenix; catalogue PX-TA1536; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Introduction to Sintilimab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade Sintilimab Biosimilar, also known as Anti-PDCD1, PD1, CD279 mAb, is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. It is a biosimilar of the original drug, Sintilimab, which was developed by the Chinese biopharmaceutical company Innovent Biologics. This biosimilar is a research grade version of the drug, meaning it is intended for use in laboratory research and not for clinical use.
Sintilimab Biosimilar is a fully humanized monoclonal antibody, meaning it is derived from human cells and has a structure similar to the body’s own antibodies. It is composed of two heavy chains and two light chains, which are connected by disulfide bonds. The antibody has a molecular weight of approximately 150 kDa.
Sintilimab Biosimilar works by binding to the PD-1 receptor on the surface of T cells, a type of immune cell. The PD-1 receptor is responsible for regulating the immune response by preventing T cells from attacking normal cells in the body. However, in cancer, the PD-1 receptor can be hijacked by tumor cells to evade the immune system. Sintilimab Biosimilar blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby allowing the immune system to recognize and attack cancer cells.
Sintilimab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer, including non-small cell lung cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma. It is also being studied in combination with other cancer therapies, such as chemotherapy and other immunotherapies.
cancer, accounting for approximately 85% of all cases. Sintilimab Biosimilar has shown significant antitumor activity in preclinical studies and has been approved in China for the treatment of advanced or metastatic NSCLC. It is currently being evaluated in clinical trials for the treatment of NSCLC in other countries.
cancer and is often diagnosed at an advanced stage. Sintilimab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of advanced HCC. It has also been approved in China for the treatment of advanced HCC.
ESCC is a type of cancer that affects the esophagus, the tube that connects the throat to the stomach. Sintilimab Biosimilar has shown significant antitumor activity in preclinical studies and is currently being evaluated in clinical trials for the treatment of ESCC. It has also been approved in China for the treatment of advanced ESCC.
Sintilimab Biosimilar is a research grade version of the original drug, Sintilimab, and is a promising therapeutic option for the treatment of various types of cancer. Its mechanism of action, targeting the PD-1 receptor, has shown significant antitumor activity in preclinical studies and is currently being evaluated in clinical trials. With its potential to improve outcomes for cancer patients, Sintilimab Biosimilar is a valuable addition to the arsenal of cancer therapies.
ProteoGenix catalogue number PX-TA1536. For research use only.
Target: Sintilimab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg, 10mg, 25mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Sintilimab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
